| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 33.579 | 6.881 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 34.387 | 8.354 | 107 | 7.952 | 39 | 34 | 23 | 32 | 7 | 0 |
| Total Expenses - EUR | 35.821 | 5.553 | 95 | 1.343 | 262 | 4 | 3 | 275 | 7 | 0 |
| Gross Profit/Loss - EUR | -1.434 | 2.801 | 12 | 6.609 | -223 | 30 | 20 | -244 | 0 | 0 |
| Net Profit/Loss - EUR | -1.434 | 2.557 | 11 | 6.372 | -224 | 29 | 19 | -244 | 0 | 0 |
| Employees | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Transylvania Pharmaceuticals Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 20.063 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 69.686 | 64.094 | 60.375 | 52.405 | 51.167 | 50.227 | 49.133 | 49.042 | 48.894 | 48.620 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 66.339 | 57.557 | 53.916 | 46.064 | 45.172 | 50.227 | 49.133 | 49.042 | 48.894 | 48.620 |
| Cash | 3.347 | 6.537 | 6.458 | 6.341 | 5.995 | 0 | 0 | 0 | 0 | 0 |
| Shareholders Funds | 43.009 | 45.128 | 44.375 | 49.933 | 48.742 | 47.847 | 46.805 | 46.706 | 46.565 | 46.305 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 46.766 | 18.966 | 15.999 | 2.473 | 2.426 | 2.380 | 2.328 | 2.335 | 2.328 | 2.315 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4941 - 4941" | |||||||||
| CAEN Financial Year |
4941
|
|||||||||
Comments - Transylvania Pharmaceuticals Srl